NCT05115292
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 20, 2021
Completion: Oct 20, 2025